Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Malaysia ETF (EWM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

iShares MSCI Malaysia ETFTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Malaysia ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares MSCI Malaysia ETF trades at $28.01, while Regeneron Pharmaceuticals Inc trades at $677.44 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.57% dividend while iShares MSCI Malaysia ETF pays none, and iShares MSCI Malaysia ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

EWMREGN
Sector
Broad Market / FactorHealth
52-Week High
$30.42$812.27
52-Week Low
$23.49$542.52
Market Cap
$69.66B
Enterprise Value
$63.61B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Malaysia ETF

EWM (iShares MSCI Malaysia ETF) trades at $28.005, down 0.3% on the day, with technical indicators showing a bullish bias despite overbought RSI readings. The ETF provides concentrated exposure to Malaysia's financial (54%) and industrial (21%) sectors, benefiting from the country's data center expansion, semiconductor ambitions, and tourism initiatives. Recent news highlights Malaysia's energy diversification efforts amid regional power demand surges.

The outlook remains constructive given Malaysia's structural growth drivers, though investors face currency risk, regional geopolitical tensions, and dependence on global semiconductor demand. Current technical strength suggests near-term upside potential, but elevated RSI levels warrant caution for entry timing.

Regeneron Pharmaceuticals Inc

Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.

Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Malaysia ETF

EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.

Read more on EWM

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN